The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
877
August 21, 1992
View Complete Issue         Table of Contents 2019 
Oral Mesalamine for Ulcerative Colitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Oral Mesalamine for Ulcerative Colitis
August 21, 1992 (Issue: 877)
An oral formulation of mesalamine (5-aminosalicylic acid, 5-ASA, Asacol - Proctor & Gamble), was recently approved by the US Food and Drug Administration (FDA) for treatment of mildly to moderately active ulcerative colitis; it has not been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Oral Mesalamine for Ulcerative Colitis
Article code: 877b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.